Adlai Nortye Ltd. American Depositary Shares (ANL)
ANL Stock Price Chart
Explore Adlai Nortye Ltd. American Depositary Shares interactive price chart. Choose custom timeframes to analyze ANL price movements and trends.
ANL Company Profile
Discover essential business fundamentals and corporate details for Adlai Nortye Ltd. American Depositary Shares (ANL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Sept 2023
Employees
123.00
Website
https://www.adlainortye.comCEO
Yang Lu
Description
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.
ANL Financial Timeline
Browse a chronological timeline of Adlai Nortye Ltd. American Depositary Shares corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 7 Aug 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 30 Apr 2025
EPS came in at -$0.22 surpassing the estimated -$0.53 by +58.49%.
Earnings released on 26 Feb 2025
EPS came in at -$0.22 surpassing the estimated -$0.53 by +58.49%.
Earnings released on 8 Aug 2024
EPS came in at -$0.53 surpassing the estimated -$1.06 by +50.15%, while revenue for the quarter reached $745.00K .
Earnings released on 20 Apr 2024
EPS came in at -$0.65 falling short of the estimated -$0.38 by -70.52%, while revenue for the quarter reached $2.50M .
Earnings released on 31 Mar 2024
EPS came in at -$0.53 , while revenue for the quarter reached $745.00K .
Earnings released on 30 Sept 2023
EPS came in at -$0.65 falling short of the estimated -$0.24 by -169.98%, while revenue for the quarter reached $2.50M , missing expectations by -50.00%.
Earnings released on 30 Jun 2023
EPS came in at -$2.49 .
Earnings released on 31 Mar 2023
EPS came in at -$0.59 .
Earnings released on 31 Dec 2022
EPS came in at -$0.87 .
Earnings released on 30 Sept 2022
EPS came in at -$0.87 .
Earnings released on 30 Jun 2022
EPS came in at -$0.14 .
Earnings released on 31 Mar 2022
EPS came in at -$0.44 .
ANL Stock Performance
Access detailed ANL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.